Cargando…

Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma

Detalles Bibliográficos
Autores principales:	Ozga, Michael, Zhao, Qiuhong, Huric, Laila, Miller, Cecelia, Rosko, Ashley, Khan, Abdullah, Umyarova, Elvira, Benson, Don, Cottini, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638414/ https://www.ncbi.nlm.nih.gov/pubmed/37949844 http://dx.doi.org/10.1038/s41408-023-00943-2

Ejemplares similares

Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma
por: Khan, Abdullah M., et al.
Publicado: (2023)

Racial differences as predictors of outcomes in young patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2022)

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2023)

Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
por: Nunnelee, Jordan, et al.
Publicado: (2022)

MMSET is the key molecular target in t(4;14) myeloma
por: Mirabella, F, et al.
Publicado: (2013)

Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
por: Nunnelee, Jordan, et al.
Publicado: (2022)

The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma
por: Longo, Joseph, et al.
Publicado: (2020)

The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis
por: Oliveira, Vanessa, et al.
Publicado: (2019)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
por: Cottini, Francesca, et al.
Publicado: (2021)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2013)

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
por: Kalff, A, et al.
Publicado: (2012)

Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)
por: Kamseng, Parin, et al.
Publicado: (2021)

Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma
por: Jia, Yunlu, et al.
Publicado: (2022)

Posttranslational modification of Aurora A‐NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma
por: Jiang, Hongmei, et al.
Publicado: (2022)

Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation
por: Wang, Jingjing, et al.
Publicado: (2022)

P807: CLASS Ⅱ FERROPTOSIS INDUCERS ARE A NOVEL THERAPEUTIC APPROACH FOR T(4;14)-POSITIVE MULTIPLE MYELOMA
por: Zhang, Jiasi, et al.
Publicado: (2023)

A Novel Function of Sphingosine Kinase 2 in the Metabolism of Sphinga-4,14-Diene Lipids
por: Couttas, Timothy Andrew, et al.
Publicado: (2020)

Implementation of KK for DELPHI (DElKK version 4.14/6)
por: Andringa, S, et al.
Publicado: (2003)

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
por: Braunstein, Zachary, et al.
Publicado: (2022)

MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)(pos) multiple myeloma indicate poor prognosis
por: Li, Feng, et al.
Publicado: (2017)

Scientific opinion on flavouring group evaluation 414 (FGE.414): 2‐hydroxy‐4‐methoxybenzaldehyde
por: Younes, Maged, et al.
Publicado: (2021)

Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma
por: Yan, J, et al.
Publicado: (2014)

(414) Low Incidence of Long COVID in Heart Transplant Recipients
por: Feinman, J., et al.
Publicado: (2023)

Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma
por: Smol, Thomas, et al.
Publicado: (2017)

Memorandum: status of analysis of experiment R414
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1978)

Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance
por: Baysal, Mehmet, et al.
Publicado: (2020)

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients
por: Calura, Enrica, et al.
Publicado: (2015)

1-Hydroxymethyl-3,12-dioxa-14-azatetracyclo[9.2.1.0(4,14).0(5,10)]tetradecane
por: Tai, Xi-Shi, et al.
Publicado: (2008)

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society
por: Abe, Yoshiaki, et al.
Publicado: (2019)

Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
por: Liu, Yang, et al.
Publicado: (2023)

The two "hit" and multiple "hit" theories of carcinogenesis.
por: Ashley, D. J.
Publicado: (1969)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Exam ref 70-414 : implementing an advanced server infrastructure
por: Suehring, Steve
Publicado: (2014)

MON-414 The Case of a Dual-Secreting Pituitary Macroadenoma
por: Malkani, Natasha, et al.
Publicado: (2019)

A Novel Nonsense Mutation (c.414G>A; p.Trp138*) in CLDN14 Causes Hearing Loss in Yemeni Families: A Case Report
por: Mohamed, Walaa Kamal Eldin, et al.
Publicado: (2019)

Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) Translocations
por: Kamachi, Kazuharu, et al.
Publicado: (2019)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

KSB Q1 2020 sales hit by coronavirus
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7m4c6av30uu4nbgmnv1ifaai5o